Interventional radiology has transformed modern medicine, enabling precise tissue sampling and minimally invasive procedures that once required open surgery. Yet these advances carry risks that demand constant vigilance. A case report published July 7, 2026, in BJR Case Reports serves as a stark reminder of how quickly complications can escalate—and how hyperbaric oxygen therapy remains a critical, sometimes life-saving intervention when air invades the cerebral circulation.
The report documents a cerebral air gas embolism occurring as a complication of CT-guided lung biopsy, a procedure performed thousands of times annually worldwide. While such embolisms are rare, occurring in approximately 0.02% to 0.06% of percutaneous lung biopsies, their consequences can be catastrophic. Without prompt recognition and treatment, cerebral air embolism carries mortality rates exceeding 20%, with many survivors experiencing permanent neurological disability.
The Pathophysiology: When Air Becomes Poison
Air gas embolism occurs when gas enters the vascular system, creating mechanical obstruction and triggering a cascade of inflammatory and ischemic injury. During CT-guided lung biopsy, the risk arises from several mechanisms: direct entry of air through the biopsy needle if it is not properly capped, creation of a bronchovenous or alveolovenous fistula that allows air to enter pulmonary veins, or inadvertent placement of the needle tip within a pulmonary vein rather than the target lesion.
The positioning of the patient during and after the procedure significantly influences risk. When patients are in an upright or semi-upright position, air bubbles in the pulmonary venous system can ascend to the arch vessels and enter the cerebral circulation. Once in the cerebral arteries, air bubbles cause both direct mechanical obstruction and secondary injury through endothelial damage, platelet activation, and complement cascade activation.
The consequences depend on the volume of air, the rate of entry, and the vascular territory affected. Small volumes may cause transient symptoms or remain asymptomatic. Larger cerebral emboli produce the classic presentation documented in the 2026 case report: sudden altered consciousness, focal neurological deficits, seizures, or cardiovascular collapse from air locking in the heart.
Emergency Recognition: The First Minutes Matter
Successful management of cerebral air gas embolism hinges on immediate recognition. The 2026 case report emphasizes that symptoms typically manifest during or immediately after the biopsy procedure, though delayed presentations up to 48 hours have been reported. Any neurological change in the context of recent lung biopsy—or any procedure involving vascular access or body cavity instrumentation—should trigger immediate consideration of air embolism.
The classic triad includes acute neurological deterioration, cardiovascular instability, and respiratory distress, though presentations vary widely. Some patients experience sudden loss of consciousness; others develop focal deficits mimicking stroke; still others present with seizures or chest pain from concomitant coronary air embolism.
Immediate interventions while arranging definitive treatment include positioning the patient in the left lateral decubitus position with the head down (Durant maneuver), which helps trap air in the right ventricle apex and prevents further cerebral embolization. High-flow oxygen should be administered immediately—not only to address hypoxemia but also to create a nitrogen gradient that accelerates absorption of nitrogen-containing air bubbles.
HBOT: The Definitive FDA-Cleared Treatment
Hyperbaric oxygen therapy represents the definitive treatment for cerebral air gas embolism, with the FDA explicitly clearing HBOT for arterial gas embolism among its thirteen approved indications. The physiological rationale is compelling and multifaceted.
At hyperbaric pressures—typically 2.8 to 3.0 atmospheres absolute (ATA) for air embolism—the diameter of gas bubbles decreases in accordance with Boyle’s law. A bubble at 3 ATA occupies one-third the volume it does at surface pressure. This mechanical reduction in bubble size can immediately restore perfusion to blocked vessels. Simultaneously, the hyperoxic environment dramatically increases the partial pressure gradient for nitrogen diffusion out of bubbles and into the surrounding tissue and blood, accelerating bubble resolution.
Beyond these mechanical effects, HBOT addresses the pathophysiological consequences of air embolism. Ischemic tissues receive supraphysiological oxygen delivery via plasma dissolution, maintaining cellular viability until perfusion is restored. HBOT reduces endothelial swelling and neutrophil adhesion, attenuating the reperfusion injury that often follows bubble resolution. The therapy also reduces cerebral edema and can lower intracranial pressure.
The 2026 case report highlights the urgency of HBOT initiation. In this patient, emergency transfer to a hyperbaric facility and prompt treatment were critical to a favorable outcome. Guidelines from the Undersea and Hyperbaric Medical Society (UHMS) recommend HBOT as soon as possible for cerebral air embolism, with treatment ideally commencing within the first six hours for maximum efficacy. However, benefit has been documented with delayed treatment, and HBOT should not be withheld based solely on time elapsed.
Procedural Safety and Prevention
While the 2026 case demonstrates successful management, prevention remains paramount. CT-guided lung biopsy safety protocols have evolved considerably, with many centers implementing measures to reduce air embolism risk. These include minimizing the time the biopsy needle remains uncapped, maintaining patients in a prone or lateral position rather than upright during and immediately after the procedure, and ensuring adequate patient education about the importance of avoiding Valsalva maneuvers.
The technical approach also matters. Needle trajectory that avoids the pulmonary hilum and major vessels reduces risk, as does avoiding biopsy through cystic or cavitary lesions where air may be under pressure. Some operators advocate for single-needle pass techniques or the use of coaxial systems that minimize the number of pleural and parenchymal punctures.
Despite these precautions, air embolism cannot be completely eliminated. The 2026 case report underscores the importance of having established emergency protocols, including rapid recognition algorithms, immediate supportive care measures, and streamlined pathways for emergent HBOT transfer when facilities are not co-located.
The FDA Safety Context: Device Risks and Clinical Benefits
The successful use of HBOT in cerebral air embolism cases exists within a broader regulatory context. In August 2025, the FDA issued a safety communication to health care providers regarding hyperbaric oxygen therapy devices, noting reports of serious injuries and deaths associated with their use. The agency emphasized the importance of following manufacturer instructions for use, ensuring fire prevention measures, proper staff training, and patient monitoring throughout treatment.
This safety communication does not diminish the well-established benefits of HBOT for FDA-cleared indications such as arterial gas embolism. Rather, it reminds practitioners that HBOT devices—like all medical equipment—carry risks when used improperly. The fire risk in hyperbaric chambers is particularly significant given the oxygen-enriched environment, and strict adherence to safety protocols is essential.
For patients with cerebral air embolism, the risk-benefit calculation strongly favors HBOT. Without treatment, mortality and severe neurological morbidity are substantial. With prompt HBOT, many patients experience complete or near-complete recovery, even after profound initial neurological deficits.
Outcomes and Long-Term Prognosis
The 2026 case report adds to a literature documenting generally favorable outcomes when cerebral air embolism is recognized and treated promptly. Series from hyperbaric medicine centers report survival rates exceeding 80% with HBOT, though neurological deficits persist in a minority of patients. Factors associated with poorer outcomes include delayed treatment initiation, larger volumes of embolized air, and coexisting cardiopulmonary disease.
Long-term follow-up of survivors is important, as some patients experience delayed neurological sequelae including cognitive impairment, seizures, or movement disorders. The mechanisms may include microvascular injury, inflammatory responses, or areas of subtle ischemic damage not immediately apparent on initial imaging.
For the interventional radiology community, each case of air embolism represents an opportunity for quality improvement. Root cause analysis, review of procedural technique, and refinement of emergency protocols can prevent future occurrences and improve outcomes when complications do arise.
Clinical Implications and Future Directions
The 2026 case report carries several important implications for clinical practice. First, it reinforces the necessity of informed consent discussions that include air embolism as a rare but serious complication of lung biopsy. Patients should understand the symptoms that would require immediate medical attention after the procedure.
Second, the case highlights the critical importance of facility preparedness. Centers performing CT-guided lung biopsy should have established relationships with hyperbaric medicine facilities, clear transfer protocols, and staff trained in the immediate management of air embolism. In regions where HBOT is not immediately available, telemedicine consultation with hyperbaric medicine specialists can guide initial management while transfer is arranged.
Third, the successful outcome demonstrates that even severe cerebral air embolism can be treated effectively when the care pathway functions optimally. The multidisciplinary coordination between interventional radiology, emergency medicine, neurology, and hyperbaric medicine—all documented in the case report—represents best practice for this emergency.
Looking forward, research continues into preventive technologies and techniques. Real-time needle tip visualization, pressure-sensing biopsy systems, and modified patient positioning protocols may further reduce the incidence of this complication. However, as long as percutaneous lung biopsy remains a vital diagnostic tool, cerebral air gas embolism will remain a rare but critical indication for emergency hyperbaric oxygen therapy.
For clinicians across specialties, the message is clear: when air enters the cerebral circulation, minutes matter. Recognition, immediate supportive care, and rapid access to HBOT can mean the difference between devastating neurological injury and full recovery.